secwatch.observer — SEC 8-K summary
======================================

Issuer:     Janux Therapeutics, Inc. (JANX)
CIK:        0001817713
Form:       8-K
Filed at:   2023-06-20T23:59:59+00:00
Accession:  0000950170-23-028982
Event type: regulatory
Sentiment:  negative
Materiality: 0.60
Item codes: 3.01, 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Janux loses majority-independent board after director exit; Nasdaq grants cure period
--------------------------------------------------------------------------------

- Independent director Peter Thompson did not stand for re-election, reducing independent directors to 4 out of 9 total.
- Nasdaq notified company of non-compliance with majority independence rule (5605(b)(1)); cure period extends to June 14, 2024.
- Board evaluating options to regain compliance within cure period.
- At annual meeting, stockholders elected Sheila Gujrathi and Alana McNulty as Class II directors.
- Ratified Ernst & Young as independent auditor for FY 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023028982/0000950170-23-028982-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1817713/000095017023028982/janx-20230614.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-028982

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer